Item 4 — Purpose of Transaction
Item 4 of the Schedule 13D is hereby amended and supplemented by the following: The responses to Item 1 Comment, Item 3, Item 5(c) and Item 6 of this Amendment No. 3 are hereby incorporated by reference herein. On June 16, 2026, TCM Partners made an in-kind distribution of an aggregate 2,275,737 shares of Common Stock to its limited partners and its general partner, proportionately based on their respective limited partnership interests, for no consideration, including 3,512 shares of Common Stock that were distributed to TCM GP, whose sole manager is Mr. McCormack. Also on June 16, 2026, TCM Partners transferred an additional 79,356 shares of Common Stock to its investment manager, TCM Strategic L.P., which is wholly-owned by Mr. McCormack. Effective July 5, 2026, Mr. McCormack's service as President and Chief Executive Officer of the Company will conclude. In connection with this transition, and pursuant to the terms of his existing agreements, Mr. McCormack will be entitled to severance benefits, including certain accelerated equity vesting and health benefit stipends. Mr. McCormack will remain on the Company's Board of Directors.